Respiratory

Description

1. Cough is an important physiological protective mechanism, but may also occur as a symptom of an underlying disorder such as asthma, gastro-oesophageal reflux disease and postnasal drip. A productive cough is characterized by the presence of sputum and may be associated with conditions such as acute bronchitis, lower respiratory tract infections, COPD and chronic bronchitis.
2. GRILINCTUS-LS^® Syrup is a combination of Levosalbutamol, Ambroxol and Guaiphenesin. Levosalbutamol (R isomer) is a selective ß2- adrenergic receptor antagonist. 
3. Increased cyclic-AMP concentrations are also associated with the inhibition of the release of mediators from the mast cells in the airways. Levosalbutamol acts as a functional agonist that relaxes the airway irrespective of the spasmogen involved, thereby protecting against all bronchoconstrictor challenges. Levosalbutamol has approximately a 2-fold greater affinity than racemic salbutamol (a 50:50 ratio of (R) and (S) isomers) for the ß2, adrenergic receptor and an approximately 100-fold greater binding affinity than S- salbutamol.
4. Ambroxol is a mucoregulator and mucolytic agent that assists in clearing mucus by its mucociliary and mucokinetic action. Ambroxol also aids in the synthesis of surfactant.
5. Guaiphenesin acts by increasing the respiratory tract fluid, reducing the viscocity of tenacious sputum and thus facilitating the expectoration of sputum. 

Indications

GRILINCTUS-LS^® Syrup is indicated for the treatment of Productive Cough associated with Bronchospasm.